🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application
Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin – Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, …
CALGARY, AB, May 10, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of its innovative psychedelic-assisted therapy solutions, announced the submission of its N-500 Phase II Psilocybin …
ATMA will use Filament’s proprietary botanical drug candidate for clinical trials
CALGARY, AB, Jan. 7, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”) has been granted a No Objection Letter (“NOL”) by Health Canada, a crucial step towards opening ATMA’s first …
The program will support greater accessibility and affordability for clients and enable therapists to share data and experiences among colleagues to increase the efficiency and effectiveness of Psychedelic-assisted Therapy.
MDMA studies combined with psychoanalysis have shown great promise in the treatment of Posttraumatic Stress Disorder (PTSD), indicating sustained decreases in PTSD symptoms.
ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada’s Section 56(1) Exemption.
The completed equity investment strengthens ties between MINDCURE and ATMA.
Copyright © 2023 ATMA
